Search results
Amgen Stock Is Having Its Best Day Since 2009. Why Wall Street Is Excited About Its Weight-Loss Drug...
Barrons.com· 29 minutes agoFEATURE Amgen stock was on track for its biggest daily gain since 2009 after the company said it saw...
Where Is Amgen Headed After the Stock Surges on Obesity Drug News?
TheStreet.com· 3 hours agoShares of Amgen (AMGN) are soaring higher Friday morning after the biopharma company's CEO gave a...
Why Shares in GE Healthcare Looked Sick This Week
Motley Fool via Yahoo Finance· 8 minutes agoHealthcare (NASDAQ: GEHC) were down 8.4% for the week as of Friday at 10 a.m. ET, according to data provided by S&P Global Market Intelligence. The move...
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
Reuters via Yahoo News· 11 minutes agoAmneal Pharmaceuticals said on Friday it had reached a deal valued at more than $270 million to...
Dow Jones Soars 400 Points As Amgen, Apple Surge; Nvidia Jumps Again, Tempts New Buyers
Investor's Business Daily· 30 minutes agoApple also raised its dividend slightly to 25 cents a share. Amgen Leads The Dow But Amgen was the...
Amgen Is 'Very Encouraged' With Its Obesity Drug. But Can It Take On Novo, Lilly Duopoly?
Investor's Business Daily· 6 minutes agoBut rather than stimulate another hormone, like Zepbound which also loops in GIP, MariTide actually...
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
Bloomberg via Yahoo Finance· 2 hours ago(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very...
Weight loss drug shortage: Zepbound and Wegovy in short supply, says FDA
BenefitsPRO· 1 day agoThe FDA anticipates limited availability through the end of the second financial quarter, or at...
Amgen 'encouraged' by weight-loss drug interim data, shares jump
Reuters via AOL· 19 hours ago(Reuters) -Amgen on Thursday said it was very encouraged after completing an interim analysis of its...
Amgen Knocks Novo Nordisk's Ozempic Stock Rally
The Wall Street Journal· 55 minutes agoAmgen’s progress on its experimental weight-loss drug offered investors a reminder that Novo Nordisk isn’t the only game in town. Novo's first-quarter...
